Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer
Alok Kumar Singh,
Monali Praharaj,
Kara A. Lombardo,
Takahiro Yoshida,
Andres Matoso,
Alex S. Baras,
Liang Zhao,
Geetha Srikrishna,
Joy Huang,
Pankaj Prasad,
Jonathan D. Powell,
Max Kates,
David McConkey,
Drew M. Pardoll,
William R. Bishai () and
Trinity J. Bivalacqua ()
Additional contact information
Alok Kumar Singh: Center for Tuberculosis Research
Monali Praharaj: Center for Tuberculosis Research
Kara A. Lombardo: Johns Hopkins University, School of Medicine, Department of Urology
Takahiro Yoshida: Hyogo Prefectural Nishinomiya Hospital
Andres Matoso: The Johns Hopkins University
Alex S. Baras: The Johns Hopkins University
Liang Zhao: The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins
Geetha Srikrishna: Center for Tuberculosis Research
Joy Huang: Center for Tuberculosis Research
Pankaj Prasad: Center for Tuberculosis Research
Jonathan D. Powell: The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins
Max Kates: Johns Hopkins University, School of Medicine, Department of Urology
David McConkey: Johns Hopkins University, School of Medicine, Department of Urology
Drew M. Pardoll: The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins
William R. Bishai: Center for Tuberculosis Research
Trinity J. Bivalacqua: Perelman School of Medicine at the University of Pennsylvania, Division of Urology, Department of Surgery
Nature Communications, 2022, vol. 13, issue 1, 1-16
Abstract:
Abstract In addition to its role as a TB vaccine, BCG has been shown to elicit heterologous protection against many other pathogens including viruses through a process termed trained immunity. Despite its potential as a broadly protective vaccine, little has been done to determine if BCG-mediated trained immunity levels can be optimized. Here we re-engineer BCG to express high levels of c-di-AMP, a PAMP recognized by stimulator of interferon genes (STING). We find that BCG overexpressing c-di-AMP elicits more potent signatures of trained immunity including higher pro-inflammatory cytokine responses, greater myeloid cell reprogramming toward inflammatory and activated states, and enhances epigenetic and metabolomic changes. In a model of bladder cancer, we also show that re-engineered BCG induces trained immunity and improved functionality. These results indicate that trained immunity levels and antitumor efficacy may be increased by modifying BCG to express higher levels of key PAMP molecules.
Date: 2022
References: View complete reference list from CitEc
Citations:
Downloads: (external link)
https://www.nature.com/articles/s41467-022-28509-z Abstract (text/html)
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-28509-z
Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/
DOI: 10.1038/s41467-022-28509-z
Access Statistics for this article
Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie
More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().